Bambuterol


Concise Prescribing Info
Indications/Uses
Persistent reversible airways obstruction.
Dosage/Direction for Use
Adult : PO 10-20 mg/day at bedtime.
Dosage Details
Oral
Persistent reversible airways obstruction
Adult: 10-20 mg once daily at bedtime.
Renal Impairment
CrCl (mL/min) Dosage
<50 Initial dose should be halved.
Hepatic Impairment
Severe: Not recommended.
Special Precautions
Patient w/ liver cirrhosis and other causes of severely impaired liver function; underlying severe heart disease (e.g. ischaemic heart disease, arrhythmia or severe heart failure); thyrotoxicosis, DM, hypertrophic cardiomyopathy, predisposition to angle closure glaucoma. Not intended for relief of acute bronchospasm or in patients w/ unstable resp disease. Moderate to severe renal impairment. Pregnancy and lactation.
Adverse Reactions
Behavioural disturbances (e.g. restlessness, agitation), tremor, headache, sleep disturbances, palpitations, muscle cramps, hypersensitivity reactions, hypokalaemia, hyperglycaemia, dizziness, hyperactivity, tachycardia, cardiac arrhythmias, myocardial ischaemia, paradoxical bronchospasm, nausea.
Overdosage
Symptoms: Headache, anxiety, tremor, nausea, tonic muscle cramps, palpitations, tachycardia and cardiac arrhythmias. Management: Consider gastric lavage and activated charcoal in severe cases. Determine acid-base balance, blood glucose and electrolytes. Monitor BP, heart rate and rhythm. For haemodynamically significant cardiac arrhythmias, the preferred antidote is a cardioselective β-blocker, but should be used w/ caution in patients w/ history of bronchospasm. Admin a vol expander when the β2-mediated reduction in peripheral vascular resistance significantly contributes to the fall in BP.
Drug Interactions
Prolonged muscle-relaxing effect of other sympathomimetics (e.g. suxamethonium). Increased risk of hypokalaemia by co-admin w/ corticosteroids, diuretics or xanthine derivatives. Partial or total inhibition of effects w/ non-selective β-blockers.
Action
Description: Bambuterol is a prodrug of terbutaline. It relaxes bronchial smooth muscle by selectively acting on β2-receptors.
Duration: At least 24 hr.
Pharmacokinetics:
Absorption: Absorbed from the GI tract (approx 20%). Bioavailability: Approx 10%. Time to peak plasma concentration: Approx 4-7 hr (terbutaline).
Distribution: Plasma protein binding: 40-50%.
Metabolism: Slowly metabolised in the liver to its active metabolite, terbutaline via hydrolysis and oxidation.
Excretion: Terminal half-life: 9-17 hr.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store below 30°C.
ATC Classification
R03CC12 - bambuterol ; Belongs to the class of adrenergics for systemic use, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
Disclaimer: This information is independently developed by MIMS based on Bambuterol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in